[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100410477":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":32,"responsibleParty":151,"collaborators":10,"id":153,"slug":154,"hasResults":155,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":155,"sex":160,"minAge":161,"maxAge":10,"enrollmentInfo":162,"targetDuration":10,"studyType":165,"phases":10,"briefSummary":166,"conditions":167,"keywords":10,"overallStatus":52,"whyStopped":10,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":178},{"fullName":5,"class":6},"IFOM ETS - The AIRC Institute of Molecular Oncology","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort of BC patients",null,"Stage-mixed cohort of at least 1500 breast cancer patients through their course of treatment, until death or a minimum of 5 years.",[13],"Other: Observational",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Observational","Retrospective cohorts and Prospective observation of standard clinical practice",[9],[20],{"name":21,"affiliation":5,"role":22},"Silvia Marsoni, MD","STUDY_CHAIR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Smeralda Rapisarda","CONTACT","+3902574303236","clinical.trials@ifom.eu",{"name":30,"role":26,"phone":31,"phoneExt":10,"email":28},"Ylenia Silvestri, PhD","+3902574303799",[33,50,63,71,83,95,107,119,130,139],{"facility":34,"status":35,"city":36,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Asst Papa Giovanni Xxiii","NOT_YET_RECRUITING","Bergamo","24127","Italy","IT",{"type":41,"coordinates":42},"Point",[43,44],9.66721,45.69601,{"lat":44,"lon":43},[47],{"name":48,"role":49,"phone":10,"phoneExt":10,"email":10},"Vittoria Fotia, MD","PRINCIPAL_INVESTIGATOR",{"facility":51,"status":52,"city":53,"state":53,"zip":54,"country":38,"countryCode":39,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Fondazione IRCCS, Istituto Nazionale dei Tumori","RECRUITING","Milan","20133",{"type":41,"coordinates":56},[57,58],9.18951,45.46427,{"lat":58,"lon":57},[61],{"name":62,"role":49,"phone":10,"phoneExt":10,"email":10},"Filippo De Braud, MD",{"facility":64,"status":52,"city":53,"state":53,"zip":54,"country":38,"countryCode":39,"cosmosGeoPoint":65,"geoPoint":67,"contacts":68},"Fondazione IRCCS, Istituto Neurologico Carlo Besta",{"type":41,"coordinates":66},[57,58],{"lat":58,"lon":57},[69],{"name":70,"role":49,"phone":10,"phoneExt":10,"email":10},"Cecilia Casali, MD",{"facility":72,"status":52,"city":73,"state":73,"zip":74,"country":38,"countryCode":39,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Azienda Ospedaliero Universitaria Maggiore della Carità di Novara","Novara","28100",{"type":41,"coordinates":76},[77,78],8.62118,45.44694,{"lat":78,"lon":77},[81],{"name":82,"role":49,"phone":10,"phoneExt":10,"email":10},"Alessandra Gennari, MD",{"facility":84,"status":52,"city":85,"state":85,"zip":86,"country":38,"countryCode":39,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Istituto Oncologico Veneto IRCCS (IOV)","Padova","35128",{"type":41,"coordinates":88},[89,90],11.14261,44.38225,{"lat":90,"lon":89},[93],{"name":94,"role":49,"phone":10,"phoneExt":10,"email":10},"Valentina Guarneri, MD",{"facility":96,"status":52,"city":97,"state":97,"zip":98,"country":38,"countryCode":39,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Fondazione IRCCS, Policlinico San Matteo Pavia","Pavia","27100",{"type":41,"coordinates":100},[101,102],9.15917,45.19205,{"lat":102,"lon":101},[105],{"name":106,"role":49,"phone":10,"phoneExt":10,"email":10},"Paolo Pedrazzoli, MD",{"facility":108,"status":52,"city":109,"state":109,"zip":110,"country":38,"countryCode":39,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Istituto Nazionale Tumori Regina Elena di Roma - Istituti Fisioterapici Ospitalieri (IFO)","Roma","00144",{"type":41,"coordinates":112},[113,114],11.10642,44.99364,{"lat":114,"lon":113},[117],{"name":118,"role":49,"phone":10,"phoneExt":10,"email":10},"Giovanni Blandino, MD",{"facility":120,"status":52,"city":53,"state":10,"zip":121,"country":38,"countryCode":39,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"IRCCS Humanitas","20089",{"type":41,"coordinates":123},[124,125],12.59836,42.78235,{"lat":125,"lon":124},[128],{"name":129,"role":49,"phone":10,"phoneExt":10,"email":10},"Alberto Zambelli, MD",{"facility":131,"status":52,"city":53,"state":10,"zip":132,"country":38,"countryCode":39,"cosmosGeoPoint":133,"geoPoint":135,"contacts":136},"IEO - Istituto Europeo di Oncologia","20141",{"type":41,"coordinates":134},[124,125],{"lat":125,"lon":124},[137],{"name":138,"role":49,"phone":10,"phoneExt":10,"email":10},"Viviana Galimberti",{"facility":140,"status":52,"city":141,"state":10,"zip":142,"country":38,"countryCode":39,"cosmosGeoPoint":143,"geoPoint":147,"contacts":148},"Azienda U.S.L. - IRCCS di Reggio Emilia","Reggio Emilia","42122",{"type":41,"coordinates":144},[145,146],10.63125,44.69825,{"lat":146,"lon":145},[149],{"name":150,"role":49,"phone":10,"phoneExt":10,"email":10},"Filippo Giovanardi, MD",{"type":152,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100410477","a-master-protocol-empowering-mechanobiology-translation-research-in-breast-cancer-100410477",false,"NCT04625023","A Master Protocol Empowering Mechanobiology Translation Research in Breast Cancer","METAMECH","Inclusion Criteria:\n\n1. Verification that the patient could not be reached for informed consent in accordance with applicable national regulations or, alternatively, TIER1 written Informed consent.\n2. Patients ≥18 years of age.\n3. Previous diagnosis of breast cancer, or a strong suspicion of BC based on clinical and radiological findings.\n4. ECOG Performance status \\\u003C 2 (only for TIER1-2).\n\nExclusion Criteria:\n\n1. Any other current malignancy or malignancy diagnosed or relapsed within the past 5 years (other than non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer)\n2. Patient unable to comply with the study protocol owing to psychological, social or geographical reasons.\n3. Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or syphilis infection.","ALL","18 Years",{"count":163,"type":164},1500,"ESTIMATED","OBSERVATIONAL","METAMECH is a master observational protocol designed to empower a bi-directional collaboration between basic and clinical research, an essential prerequisite to feed and implement precision oncology.\n\nMETAMECH will follow a stage-mixed cohort of at least 500 patients through their course of treatments, until death or a minimum of 5 years. Patients will be longitudinally sampled and matched clinical data (including imaging) will be collected. Via a multi-tiered informed consensus process, METAMECH will also allow to develop companion diagnostics for molecular enrichment strategies in AIRC-driven proof-of-concept trials.",[168],"Breast Cancer","2025-04-29",{"date":171,"type":172},"2025-05-01","ACTUAL",{"date":174,"type":172},"2020-07-16",{"date":176,"type":164},"2026-12",{"name":5,"class":6},10]